(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 145.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.68%.
Abeona Therapeutics's revenue in 2026 is $14,540,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,853,897,647, with the lowest ABEO revenue forecast at $2,809,518,628, and the highest ABEO revenue forecast at $5,210,724,045. On average, 9 Wall Street analysts forecast ABEO's revenue for 2027 to be $8,120,098,166, with the lowest ABEO revenue forecast at $5,283,905,810, and the highest ABEO revenue forecast at $12,043,073,927.
In 2028, ABEO is forecast to generate $12,282,453,532 in revenue, with the lowest revenue forecast at $8,199,321,416 and the highest revenue forecast at $16,355,896,474.